Research by the CRC for Oral Health Science has resulted in 12 patent families:

1. Antimicrobial composition - improvement to Kappacin™.

2. Antigenic complex for the diagnosis and treatment of Pophyromonas gingivalis infection - relevant to the development of vaccines, diagnostics and pharmaceuticals for periodontal disease.

3. Stabilised calcium phosphate complexes - improvement to the CPP-ACP (casein phosphopeptide - amorphous calcium phosphate) complex.

4. Dental mineralisation - improvement to the CPP-ACP complex.

5. Ionic complexes - improvement to the CPP-ACP complex.

6. Composition and methods for dental mineralisation - improvement to the CPP-ACP complex.

7. Treponema denticola polypeptides useful in the prevention of periodontal disease.

8. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease.

9. Bioactive delivery device - relevant to professional dental services.

10. Immunology treatment for biofilms - relevant to development of vaccines, diagnostics and pharmaceuticals for periodontal disease.

11. Biofilm treatment - relevant to development of vaccines, diagnostics and pharmaceuticals for periodontal disease.

12. Antibodies for the treatment of periodontal disease - relevant to development of vaccines, diagnostics and pharmaceuticals for periodontal disease.